Appendix II — L — Decisions Cited — L
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
LaBounty Mfg. Inc. v. United States Int’l Trade Comm’n, 958 F.2d 1066, 22 USPQ2d 1025 (Fed. Cir. 1992) 2004 , 2133.03 , 2133.03(e) , 2133.03(e)(2)
Lafferty, Ex parte, 190 USPQ 202 (Bd. App. 1975) 1403
L.A. Gear, Inc. v. Thom McAn Shoe Co., 988 F.2d 1117, 25 USPQ2d 1913 (Fed. Cir. 1993) 1504.01(c)
Lalu, In re, 747 F.2d 703, 223 USPQ 1257 (Fed. Cir. 1984) 2144.09
Lamb, In re, 286 F.2d 610, 128 USPQ 539 (CCPA 1961) 1504.03
Lamberti, In re, 545 F.2d 747, 192 USPQ 278 (CCPA 1976) 2144.01
Lampi Corp. v. American Power Products Inc., 228 F.3d 1365, 56 USPQ2d 1445 (Fed. Cir. 2000) 2111.03
Lancaster, Ex parte, 151 USPQ 713, 1966 C.D. 20, 833 O.G. 8 (Bd. App. 1965) 1504.02
Land, In re, 368 F.2d 866, 151 USPQ 621 (CCPA 1966) 2136.04 , 2136.05
Lander, Ex parte, 223 USPQ 687 (Bd. App. 1983) 1504.02
Lange v. Comm’r, 352 F. Supp 116, 176 USPQ 162 (D. D.C. 1972) 1701.01
Langenhoven, In re, 458 F.2d 132, 173 USPQ 426 (CCPA 1972) 2809.01
Langer, In re, 465 F.2d 896, 175 USPQ 169 (CCPA 1972) 2144.09
Langer, In re, 503 F.2d 1380, 183 USPQ 288 (CCPA 1974) 2107.02 , 2107.03 , 2124
Langer v. Kaufman, 465 F.2d 915, 175 USPQ 172 (CCPA 1972) 2138.04
Lanham, In re, 1 USPQ2d 1877 (Comm’r Pat. 1986) 2258
Lantech Inc. v. Kaufman Co. of Ohio, Inc., 878 F.2d 1446, 12 USPQ2d 1076 (Fed. Cir. 1989) 2145
Lapworth, In re, 451 F.2d 1094, 172 USPQ 129 (CCPA 1971) 1504
Larsen, In re, 10 Fed. App'x. 890 (Fed. Cir. 2001) 2173.02 , 2173.05(e)
Larson, In re, 340 F.2d 965, 144 USPQ 347 (CCPA 1965) 2144.04
Larson v. Classic Corp., 683 F. Supp. 1202, 7 USPQ2d 1747 (N.D. Ill. 1988) 1504.01(c)
Lawrence, Ex parte, 70 USPQ 326, 1946 C.D. 1 (Comm’r Pat. 1946) 1457 , 1509
Leapfrog Enterprises, Inc. v. Fischer Price, Inc., 485 F.3d 1157, 82 USPQ2d 1687 (Fed. Cir. 2007) 2114 , 2143 , 2143.01 , 2145
Lee, Ex parte, 31 USPQ2d 1105 (Bd. Pat. App. & Inter. 1993) 2131.03 , 2158.01
Lee, In re, 199 USPQ 108 (Comm’r Pat. 1978) 803
Lee, In re, 277 F.3d 1338, 61 USPQ2d 1430 (Fed. Cir. 2002) 2141
Lee Pharmaceutical v. Kreps, 577 F.2d 610, 198 USPQ 601 (9th Cir. 1978) 2127
Lee v. Dayton-Hudson Corp., 838 F.2d 1186, 5 USPQ2d 1625 (Fed. Cir. 1988) 1504
Leggett v. Avery, 101 U.S. 256 (1879) 1490
LeGrice, In re, 301 F.2d 929, 133 USPQ 365 (CCPA 1962) 2121.03 , 2152.02(b)
Leithem, In re, 661 F.3d 1316, 100 USPQ2d 1155 (Fed. Cir. 2011) 1207.03
Lemelson, In re, 397 F.2d 1006, 158 USPQ 275 (CCPA 1968) 2123
Lemoine, Ex parte, 46 USPQ2d 1420 (Bd. Pat. App. & Inter. 1994) 1204
LendingTree, LLC v. Zillow, Inc., 656 Fed. App'x. 991 (Fed. Cir. 2016) 2106.05(a)
Leo Pharm. Prod., Ltd. v. Rea, 726 F.3d 1346, 107 USPQ2d 1943 (Fed. Cir. 2013) 2145
Le Roy v. Tatham, 55 U.S. (14 How.) 156 (1852) 2106.04 , 2106.04(a) , 2106.04(b)
Leshin, In re, 277 F.2d 197, 125 USPQ 416 (CCPA 1960) 2144.07
Leslie, In re, 547 F.2d 116, 192 USPQ 427 (CCPA 1977) 1503.01 , 1504.03
Levengood, Ex parte, 28 USPQ2d 1300 (Bd. Pat. App. & Inter. 1993) 2143.01 , 2144
Levy, Ex parte, 17 USPQ2d 1461 (Bd. Pat. App. & Inter. 1990) 2112
Liebel-Flarsheim Co. v. Medrad Inc., 358 F.3d 898, 69 USPQ2d 1801 (Fed. Cir. 2004) 2111.01
Lilienfeld, In re, 67 F.2d 920, 20 USPQ 53 (CCPA 1933) 2144.05
Lincoln Engineering Co. v. Stewart-Warner Corp., 303 U.S. 545, 37 USPQ 1 (1938) 2173.05(j)
Lindberg, In re, 194 F.2d 732, 93 USPQ 23 (CCPA 1952) 2144.04
Lindell, In re, 385 F.2d 453, 155 USPQ 521 (CCPA 1967) 716.01(c)
Lindemann Maschinenfabrik GMBH v. American Hoist & Derrick Co., 730 F.2d 1452, 221 USPQ 481 (Fed. Cir. 1984) 716.03 , 2164.01 , 2164.05(a)
Lindner, In re, 457 F.2d 506, 173 USPQ 356 (CCPA 1972) 716.01(c) , 716.02(d) , 2145
Linear Tech. Corp. v. Impala Linear Corp., 379 F.3d 1311, 72 USPQ2d 1065 (Fed. Cir. 2004) 2181
Linear Tech. Corp. v. Micrel, Inc., 275 F.3d 1040, 61 USPQ2d 1225 (Fed. Cir. 2001) 2133.03(b)
Links, Ex parte, 184 USPQ 429 (Bd. App. 1974) 2135.01
Lintner, In re, 458 F.2d 1013, 173 USPQ 560 (CCPA 1972) 2141 , 2142 , 2143.01 , 2144 , 2144.08 , 2145
Liqwd, Inc. v. L’Oreal USA, Inc., 941 F.3d 1133 (Fed. Cir. 2019) 716.06
Lister, In re, 583 F.3d 1307, 92 USPQ2d 1225 (Fed. Cir. 2009) 2128.02 , 2152.02(e)
Litchfield v. Eigen, 535 F.2d 72, 190 USPQ 113 (CCPA 1976) 2138.06
Litton Systems, Inc. v. Whirlpool Corp., 728 F.2d 1423, 221 USPQ 97 (Fed. Cir. 1984) 601.01(e) , 716.03(b) , 1504.03
LizardTech, Inc. v. Earth Resource Mapping, Inc., 424 F.3d 1336, 76 USPQ2d 1724 (Fed. Cir. 2005) 2161.01 , 2163
Lockheed Aircraft Corporation v. United States, 193 USPQ 449 (Ct. Cl. 1977) 2183 , 2184
Lockwood v. American Airlines, Inc., 107 F.3d 1505, 41 USPQ2d 1961 (Fed. Cir. 1997) 2133.03(a) , 2163 , 2163.02
Lohman, Ex parte, 1912 C.D. 336, 184 O.G. 287 (Comm’r Pat. 1912) 1503.02
Lonardo, In re, 119 F.3d 960, 43 USPQ2d 1262 (Fed. Cir. 1997) 804 , 2217 , 2258
Longi, In re, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985) 804 , 1504.06
Lopresti, In re, 333 F.2d 932, 142 USPQ 177 (CCPA 1964) 715
Lorenz v. Finkl, 333 F.2d 885, 142 USPQ 26 (CCPA 1964) 711.03(c)
Loughlin v. Ling, 684 F.3d 1289, 103 USPQ2d 1413 (Fed. Cir. 2012) 2304.02(c)
Lowry, In re, 32 F.3d 1579, 32 USPQ2d 1031 (Fed. Cir. 1994) 2111.05
Luck, In re, 476 F.2d 650, 177 USPQ 523 (CCPA 1973) 2173.05(o)
Ludtke, In re, 441 F.2d 660, 169 USPQ 563 (CCPA 1971) 2112.01 , 2114
Lukach, In re, 442 F.2d 967, 169 USPQ 795 (CCPA 1971) 211.05 , 2152.02(b) , 2163 , 2163.05
Lumenyte Int’l Corp. v. Cable Lite Corp., 92 F.3d 1206 (Fed. Cir. 1996) 711.03(c)
Lund, In re, 376 F.2d 982, 153 USPQ 625 (CCPA 1967) 901.01 , 901.02 , 2127 , 2136.02
Lundak, In re, 773 F.2d 1216, 227 USPQ 90 (Fed. Cir. 1985) 2163 , 2164.06 , 2164.06(a) , 2406.01
Lutzker v. Plet, 843 F.2d 1364, 6 USPQ2d 1370 (Fed. Cir. 1988) 2138.03
Lyell, Ex parte, 17 USPQ2d 1548 (Bd. Pat. App. & Inter. 1990) 2173.05(p)
Cited authority
- 2004 Aids to Compliance With Duty of Disclosure
- 2133.03 Rejections Based on “Public Use” or “On Sale”
- 2133.03(e) Permitted Activity; Experimental Use
- 2133.03(e)(2) Intent
- 1403 Diligence in Filing
- 1504.01(c) Lack of Ornamentality
- 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)
- 1504.03 Nonobviousness
- 2144.01 Implicit Disclosure
- 2111.03 Transitional Phrases
- 1504.02 Novelty
- 2136.04 Different Inventive Entity; Meaning of “By Another”
- 2136.05 Overcoming a Rejection Under Pre-AIA 35 U.S.C. 102(e)
- 1701.01 Office Personnel Not To Testify
- 2809.01 Information Relating to the Correction of Factual Information
- 2107.02 Procedural Considerations Related to Rejections for Lack of Utility
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 2124 Exception to the Rule That the Reference Must be Prior Art
- 2138.04 “Conception”
- 2258 Scope of Ex Parte Reexamination
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 1504 Examination
- 2173.02 Determining Whether Claim Language is Definite
- 2173.05(e) Lack of Antecedent Basis
- 2144.04 Legal Precedent as Source of Supporting Rationale
- 1457 Design Reissue Applications and Patents
- 1509 Reissue of a Design Patent
- 2114 Apparatus and Article Claims — Functional Language
- 2143 Examples of Basic Requirements of a Prima Facie Case of Obviousness
- 2143.01 Suggestion or Motivation To Modify the References
- 2131.03 Anticipation of Ranges
- 2158.01 Form Paragraphs for Use in Rejections Under AIA 35 U.S.C. 103
- 803 Restriction — When Proper
- 2141 Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103
- 2127 Domestic and Foreign Patent Applications as Prior Art
- 1490 Disclaimers
- 2121.03 Plant Genetics — What Constitutes Enabling Prior Art
- 2152.02(b) Described in a Printed Publication
- 1207.03 New Ground of Rejection in Examiner’s Answer
- 2123 Rejection Over Prior Art’s Broad Disclosure Instead of Preferred Embodiments
- 1204 Notice of Appeal
- 2106.05(a) Improvements to the Functioning of a Computer or To Any Other Technology or Technical Field
- 2106.04 Eligibility Step 2A: Whether a Claim is Directed to a Judicial Exception
- 2106.04(a) Abstract Ideas
- 2106.04(b) Laws of Nature, Natural Phenomena & Products of Nature
- 2144.07 Art Recognized Suitability for an Intended Purpose
- 1503.01 Specification
- 2144 Supporting a Rejection Under 35 U.S.C. 103
- 2112 Requirements of Rejection Based on Inherency; Burden of Proof
- 2111.01 Plain Meaning
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 2173.05(j) Old Combination
- 716.01(c) Probative Value of Objective Evidence
- 716.03 Commercial Success
- 2164.01 Test of Enablement
- 2164.05(a) Specification Must Be Enabling as of the Filing Date
- 716.02(d) Unexpected Results Commensurate in Scope With Claimed Invention
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 2133.03(b) “On Sale”
- 2135.01 The Four Requirements of Pre-AIA 35 U.S.C. 102(d)
- 2142 Legal Concept of Prima Facie Obviousness
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 716.06 Copying
- 2128.02 Date Publication Is Available as a Reference
- 2152.02(e) Otherwise Available to the Public
- 2138.06 “Reasonable Diligence”
- 601.01(e) Nonprovisional Application Filed Without at Least One Claim
- 716.03(b) Commercial Success Derived From Claimed Invention
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2183 Making a Prima Facie Case of Equivalence
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made
- 2133.03(a) “Public Use”
- 2163.02 Standard for Determining Compliance With the Written Description Requirement
- 1503.02 Drawing
- 804 Definition of Double Patenting
- 2217 Statement Applying Prior Art in a Request Filed under 35 U.S.C. 302
- 1504.06 Double Patenting
- 715 Swearing Behind a Reference — Affidavit or Declaration Under 37 CFR 1.131(a)
- 711.03(c) Petitions Relating to Abandonment
- 2304.02(c) Explaining Priority
- 2111.05 Functional and Nonfunctional Descriptive Material
- 2173.05(o) Double Inclusion
- 2112.01 Composition, Product, and Apparatus Claims
- 211.05 Sufficiency of Disclosure in Prior-Filed Application
- 2163.05 Changes to the Scope of Claims
- 901.01 Canceled Matter in U.S. Patent Files
- 901.02 Abandoned Applications
- 2136.02 Content of the Prior Art Available Against the Claims
- 2164.06 Quantity of Experimentation
- 2164.06(a) Examples of Enablement Issues-Missing Information
- 2406.01 Description in Application Specification
- 2138.03 “By Another Who Has Not Abandoned, Suppressed, or Concealed It”
- 2173.05(p) Claim Directed to Product-By- Process or Product and Process